Polbionica

Business Profile
Polbionica in an innovative biotechnology company developing a world-wide pioneer project of 3D bioprinting of the pancreas - a fully functional organ made of
living cells that effectively produces insulin and glucagon. A bionic pancreas transplant to a patient with type 1 diabetes will allow the patient to be cured and return
to functioning in society as a fully healthy person.
Our mission is to significantly improve the quality of life of diabetic patients around the world by introducing 3D printing of the bionic pancreas into clinical
practice. The results of the research proved that our bionic pancreas is an organ that will restore the body's ability to regulate blood sugar levels.
Web Address
https://polbionica.com/
Main Sector
Medical Technology
Year Founded
2015
Technology Overview
Polbionica is an innovative biotechnology company that conducts research on the 3D bionic pancreas and boldly thinks about the future.
The use of the bionic pancreas in clinical practice will revolutionize the treatment of diabetes and will become one of the greatest medical successes of the 21st
century.
During the work on the 3D bioprinting project of the bionic pancreas, we have created proprietary products that are key to the development of 3D bioprinting. These
are specialized bioinks tailored to individual needs, a bioreactor - a proprietary device for maintaining the vital parameters of organs in normothermic conditions,
and innovative 3D bioprinting methods.
Supporting Metrics or Evidence
3D-bioprinted bionic pancreas transplanted into pigs with stable flow trough the organ.
Alliances and Collaborations
1. University of Chicago (USA)
2. University of Leiden (Netherlands)
3. Warsaw Medical University (Poland)
4. MediSpace LTD. (Warsaw, Poland)
5. Center for Advanced Technology, Adam Mickiewicz University (Poznań, Poland)
6. Pomeranian Medical University
7. AGH University of Science and Technology
Current Investors
2 private investors.
1st investment round 29.05.2020 USD 0,53 m
2nd investment round 15.09.2021 USD 0,77 m
Management Team Highlights
CEO Michał Wszoła, MD, PhD
- founder & the main inventor in Polbionica,
- active transplantologist - +20 years of experience in the field of pancreas and islet transplantation,
- pioneer scientist - participated in the first pancreas-only transplant (2010) and the first exchange of kidney pairs between family donors (2015), also performed first
endoscopic transplantation of pancreatic islets under the gastric mucosa in the world (2013),
- successful entrepreneur – founder of medizzy.com, medical learning platform,
- laureate of numerous awards and distinctions, including the Golden Cross of Merit from the President of Poland.
CFO Filip Fertner
- +20 years practical experience in the field of economics and finance, including financial analysis of enterprises,
- experience in managing a public company (Inwestycje Alternatywne Profit S.A.), where he supervised the performance of information duties and corporate order,
- experience in practical management of complex business projects in an international environment (fluent in English, French, German, Italian and Russian).
CTO, R&D Manager Marta Klak PhD
Project Management & Investor Relations Lead Joanna Hetnarowicz
General Surgeon and Transplant Medicine Specialist Andrzej Berman MD, PhD
Biochemical Laboratory Manager Sylwester Domański
Mechatronic Engineer, 3D Printing Specialist Tomasz Dobrzański
IT&Technical Manager Wiktor Witkowski
Compliance Officer Arkadiusz Leloch
QA Specialist Marcin Bąder

Rafal Mikolajczuk
Member of the Investment Team
Joanna Hetnarowicz
Investment Team Lead